MAP2K7 and neoplasm: The MAPK pathway activates YY1 expression, and its inhibition by MEK inhibitors leads to inhibiting both PD-1 and YY1 expressions and showing stronger anti-tumor effects than seen with just the PD-1 antibody [73].